USA: +1.610.230.0150
Europe: +44.330.122.0695
Central/Eastern Europe: +30.693.227.9127
Asia/Pacific: +03.2713.1956
Israel/Middle East: +972.77.693.5033
Media Center

Media Coverage

InClinica is regularly featured in regional, national, and international publications and other media outlets. This media coverage highlights our leadership in a variety of areas.

May 2017

Hepatitis Market Update

In just a few short years, hepatitis infections could go from a serious disease to one that will be rare. Pharmaceutical companies have done much to address hepatitis in recent years. Today, hepatitis B is preventable with vaccination, and recent advances in treatment have made hepatitis C curable. [more]

PharmaVoice

April 2, 2017

Future of drug development likely Asia-centric, says InClinica’s Yablon

This week we get thoughts and ideas from global clinical contract research organisation, InClinica’s executive vice-president and general manager (Asia-Pacific), Jeffrey Scott Yablon. [more]

The Sun Daily

March 2017

VIDEO: The State of Clinical Research in Malaysia

Jeffrey Scott Yablon, Executive Vice President and General Manager of InClinica, Asia/Pacific is interviewed by Bernama Today focusing on clinical research and its potential for growth in Malaysia. [more]

Bernama Today

March 2017

Sample Size Expansion

InClinica finds clinical research opportunities in Malaysia, as well as the region. [more]

Business Times

February 16, 2017

Taking the road to medical innovation

Clinical research is defined as the medical field involving the discovery of new drugs, medical devices or medical protocol. If you think clinical research is something done by people in lab coats in hospitals, you’re not wrong. [more]

Focusweek

January 23, 2017

When it comes to diabetes, will marketers break with tradition?

The fiercely competitive diabetes drug market is in line for a dramatic overhaul, one that would place more emphasis than ever on the well-being of the consumer. [more]

MM&M

December 24, 2016

Malaysia: A Base for Clinical Development?

InClinica executive vice president and general manager (Asia-Pacific) Jeffrey Scott Yablon says Malaysia can be the leader in ASEAN clinical development over the next ten years if the industry continues to grow, evolve and get support from the government. [more]

Public Private Cover Story | Malaysia SME P&P 04 December 24, 2016 – January 6, 2017

December 23, 2016

As CROs Eye Asia, Inclinica Chooses Malaysia

Jeffrey S. Yablon is the Executive Vice President and General Manager for Asia Pacific of InClinica, a US-based clinical Contract Research Organisation (CRO). He joins us on the Breakfast Grille to discuss the CRO business model and why the company has chosen Malaysia as its regional hub. [more]

BFM 89.9

November 30, 2016

WCTD 2016 (World Congress on Clinical Trials in Diabetes)

Mr. James Nolan, CEO of the contract research organization InClinica (Wayne, PA), highlighted seven key challenges for enrollment in modern clinical trials from an industry perspective. [more]

Close Concerns

November 30, 2016

InClinica CEO Speaks To World Congress On Clinical Trials In Diabetes

James Nolan, CEO of InClinica, Inc. ‒ a global, clinical CRO ‒ will present two lectures to the World Congress on Clinical Trials in Diabetes on Wednesday, November 30 in Berlin. [more]

BioSpace

November 15, 2016

Diabesity Highlighted

Diabetes expert and researcher Professor Paul Zimmet AO delivered a talk on Diabetes In The Asia Pacific Region: Current and Future Trends, at the International Medical University. The talk highlighted the prevalence of Diabesity (obesity and type 2 diabetes) in Asia particularly in China, India, Singapore and Malaysia where economic progression and prosperity coupled with an overindulgence in rich, fatty foods and a sedentary lifestyle has resulted in an alarming increase in type 2 diabetes among the young.

The New Straits Times

November 7, 2016

InClinica expands global operations with exec hires in the U.S. and Europe

Velocity Fund Partners clearly has big plans for its newly acquired and relaunched CRO InClinica. Since the acquisition was announced in August, InClinica has been in a restless hiring mood, appointing three regional VPs of business development in the U.S. and Europe. [more]

FierceBioTech

October 18, 2016

US-based, PE-backed InClinica sets up Asia Pacific headquarter in KL

US-based clinical contract research organization (CRO) InClinica has opened a new regional head-office in Kuala Lumpur in a bid to expand its global network of clinical research in Asia Pacific. [more]

Deal Street Asia

August 18, 2016

InClinica Expands European Presence

InClinica, a global, clinical CRO, announced that Dr. Thomas Morris, has been appointed Medical Director of InClinica Ltd., representing the company’s European operations. [more]

BioSpace

August 4, 2016

Velocity Fund launches InClinica from acquired CRO IndiPharm

Pittsburgh’s Velocity Fund Partners has picked up CRO IndiPharm for an undisclosed amount, renaming the Philadelphia firm InClinica. [more]

FierceBioTech

August 3, 2016

Former Highmark CEO’s private equity fund makes acquisition

The private equity fund launched earlier in 2016 by former Highmark Inc. CEO Kenneth Melani has acquired a company. [more]

Pittsburgh Business Times

August 3, 2016

Valley Forge CRO gets new owner, new name

Velocity Fund Partners, a Pittsburgh private equity company, has acquired Valley Forge, Pennsylvania-based clinical contract research organization Indipharm and is relaunching the CRO as InClinica. [more]

Philadelphia Business Journal